BRIEF-Tenax Therapeutics Announces Global License Amendment That Expands Rights To Levosimendan

Reuters02-20

Feb 20 (Reuters) - Tenax Therapeutics Inc :

* TENAX THERAPEUTICS ANNOUNCES GLOBAL LICENSE AMENDMENT THAT SIGNIFICANTLY EXPANDS RIGHTS TO LEVOSIMENDAN

* AMENDMENT TO EXISTING AGREEMENT WITH ORION CORPORATION EXPANDS CO'S TERRITORY RIGHTS FROM NORTH AMERICA TO ENTIRE WORLD

* TENAX THERAPEUTICS - MODIFIED MILESTONE PROVISIONS, INCLUDING PAYMENT FOR REGULATORY APPROVAL IN JAPAN

* : IMPROVED NET SALES ROYALTY RATE STRUCTURE, NOW RANGING FROM HIGH SINGLE-DIGIT TO LOW-TEEN PERCENTAGES

* THROUGH AMENDMENT, TENAX GAINS GLOBAL DEVELOPMENT, COMMERCIAL, & IP RIGHTS FOR ORAL AND SUBCUTANEOUS FORMULATIONS IN PH-HFPEF

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2412837170?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-02-20 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2412837170","market":"us","top_or_hot":-1,"title":"BRIEF-Tenax Therapeutics Announces Global License Amendment That Expands Rights To Levosimendan","media":"Reuters","content":"<html><body><p>Feb 20 (Reuters) - Tenax Therapeutics Inc   :</p><p>   * TENAX THERAPEUTICS ANNOUNCES GLOBAL LICENSE AMENDMENT THAT SIGNIFICANTLY EXPANDS RIGHTS TO LEVOSIMENDAN</p><p>   * AMENDMENT TO EXISTING AGREEMENT WITH ORION CORPORATION EXPANDS CO'S TERRITORY RIGHTS FROM NORTH AMERICA TO ENTIRE WORLD</p><p>   * TENAX THERAPEUTICS - MODIFIED MILESTONE PROVISIONS, INCLUDING  PAYMENT FOR REGULATORY APPROVAL IN JAPAN</p><p>   * : IMPROVED NET SALES ROYALTY RATE STRUCTURE, NOW RANGING FROM HIGH SINGLE-DIGIT TO LOW-TEEN PERCENTAGES</p><p>   * THROUGH AMENDMENT, TENAX GAINS GLOBAL DEVELOPMENT, COMMERCIAL, &amp; IP RIGHTS FOR ORAL AND SUBCUTANEOUS FORMULATIONS IN PH-HFPEF</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Tenax Therapeutics Announces Global License Amendment That Expands Rights To Levosimendan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Tenax Therapeutics Announces Global License Amendment That Expands Rights To Levosimendan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-20 21:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Feb 20 (Reuters) - Tenax Therapeutics Inc   :   * TENAX THERAPEUTICS ANNOUNCES GLOBAL LICENSE AMENDMENT THAT SIGNIFICANTLY EXPANDS RIGHTS TO LEVOSIMENDAN   * AMENDMENT TO EXISTING AGREEMENT WITH ORION...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TENX","symbol_name":"Tenax Therapeutics, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2412837170","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2412837170","pubTimestamp":1708436536,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Feb 20  - Tenax Therapeutics Inc   :   * TENAX THERAPEUTICS ANNOUNCES GLOBAL LICENSE AMENDMENT THAT SIGNIFICANTLY EXPANDS RIGHTS TO LEVOSIMENDAN   * AMENDMENT TO EXISTING AGREEMENT WITH ORION CORPORATION EXPANDS CO'S TERRITORY RIGHTS FROM NORTH AMERICA TO ENTIRE WORLD   * TENAX THERAPEUTICS - MODIFIED MILESTONE PROVISIONS, INCLUDING  PAYMENT FOR REGULATORY APPROVAL IN JAPAN   * : IMPROVED NET SALES ROYALTY RATE STRUCTURE, NOW RANGING FROM HIGH SINGLE-DIGIT TO LOW-TEEN PERCENTAGES   * THROUGH AMENDMENT, TENAX GAINS GLOBAL DEVELOPMENT, COMMERCIAL, & IP RIGHTS FOR ORAL AND SUBCUTANEOUS FORMULATIONS IN PH-HFPEFSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TENX":"Tenax Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"简介-Tenax Therapeutics宣布全球许可修正案，扩大左西孟旦的权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TENX":1},"content_text":"Feb 20 (Reuters) - Tenax Therapeutics Inc   :   * TENAX THERAPEUTICS ANNOUNCES GLOBAL LICENSE AMENDMENT THAT SIGNIFICANTLY EXPANDS RIGHTS TO LEVOSIMENDAN   * AMENDMENT TO EXISTING AGREEMENT WITH ORION CORPORATION EXPANDS CO'S TERRITORY RIGHTS FROM NORTH AMERICA TO ENTIRE WORLD   * TENAX THERAPEUTICS - MODIFIED MILESTONE PROVISIONS, INCLUDING  PAYMENT FOR REGULATORY APPROVAL IN JAPAN   * : IMPROVED NET SALES ROYALTY RATE STRUCTURE, NOW RANGING FROM HIGH SINGLE-DIGIT TO LOW-TEEN PERCENTAGES   * THROUGH AMENDMENT, TENAX GAINS GLOBAL DEVELOPMENT, COMMERCIAL, & IP RIGHTS FOR ORAL AND SUBCUTANEOUS FORMULATIONS IN PH-HFPEFSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2412837170"}